ATE129409T1 - Neue verwendung von peptidderivat. - Google Patents
Neue verwendung von peptidderivat.Info
- Publication number
- ATE129409T1 ATE129409T1 AT91121403T AT91121403T ATE129409T1 AT E129409 T1 ATE129409 T1 AT E129409T1 AT 91121403 T AT91121403 T AT 91121403T AT 91121403 T AT91121403 T AT 91121403T AT E129409 T1 ATE129409 T1 AT E129409T1
- Authority
- AT
- Austria
- Prior art keywords
- hydroxy
- protected
- peptide derivative
- chem
- pharmaceutically acceptable
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP41829890 | 1990-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE129409T1 true ATE129409T1 (de) | 1995-11-15 |
Family
ID=18526172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91121403T ATE129409T1 (de) | 1990-12-21 | 1991-12-13 | Neue verwendung von peptidderivat. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5616556A (de) |
| EP (1) | EP0498069B1 (de) |
| JP (2) | JPH0710778B2 (de) |
| KR (1) | KR100235150B1 (de) |
| AT (1) | ATE129409T1 (de) |
| CA (1) | CA2058168A1 (de) |
| DE (1) | DE69114117T2 (de) |
| DK (1) | DK0498069T3 (de) |
| TW (2) | TW213862B (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728166A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Composition topique contenant un antagoniste de substance p |
| FR2728165A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene |
| FR2728169A1 (fr) | 1994-12-19 | 1996-06-21 | Oreal | Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales |
| FR2741262B1 (fr) | 1995-11-20 | 1999-03-05 | Oreal | Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene |
| MXPA02004330A (es) | 1999-11-03 | 2004-07-30 | Albany Molecular Res Inc | Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.. |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| CN100430401C (zh) | 2000-07-11 | 2008-11-05 | Amr科技公司 | 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途 |
| CN103880827B (zh) | 2004-07-15 | 2017-01-04 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| UA95454C2 (uk) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| RS51780B (sr) | 2007-01-10 | 2011-12-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. | Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp) |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| EP2413932A4 (de) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | Hemmer der akt-aktivität |
| EP2429295B1 (de) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl-, heteroaryl- und heterocyclen-substituierte tetrahydroisochinoline und ihre verwendung |
| KR101830447B1 (ko) | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
| US8815894B2 (en) | 2009-05-12 | 2014-08-26 | Bristol-Myers Squibb Company | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| UA109417C2 (uk) | 2009-10-14 | 2015-08-25 | Мерк Шарп Енд Доме Корп. | ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| LT2606134T (lt) | 2010-08-17 | 2019-07-25 | Sirna Therapeutics, Inc. | Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| EP2632472B1 (de) | 2010-10-29 | 2017-12-13 | Sirna Therapeutics, Inc. | Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina) |
| US9351965B2 (en) | 2010-12-21 | 2016-05-31 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3453762B1 (de) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| EP2900241B1 (de) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Neuartige verbindungen als erk-hemmer |
| SI2925888T1 (en) | 2012-11-28 | 2018-02-28 | Merck Sharp & Dohme Corp. | Compounds and methods for the treatment of cancer |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| EP2951180B1 (de) | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8-substituierte purine als hdm2-inhibitoren |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| EP3294339B1 (de) * | 2015-05-15 | 2020-12-02 | The Regents Of The University Of Michigan | Verfahren und zusammensetzungen zur behandlung von arthritis |
| EP3525785B1 (de) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5-inhibitoren |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833668B1 (de) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| TWI681301B (zh) * | 2018-09-07 | 2020-01-01 | 聚英企業管理顧問股份有限公司 | 可統計分類數量的搜尋裝置與方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8807921D0 (en) * | 1988-04-05 | 1988-05-05 | Fujisawa Pharmaceutical Co | Ws-9326 & its derivatives |
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| ZA903856B (en) * | 1989-06-02 | 1991-05-29 | Fujisawa Pharmaceutical Co | Preparation of fri15224 substance for parenteral administration |
| US5164374A (en) * | 1990-12-17 | 1992-11-17 | Monsanto Company | Use of oligosaccharides for treatment of arthritis |
-
1991
- 1991-12-13 DK DK91121403.9T patent/DK0498069T3/da active
- 1991-12-13 DE DE69114117T patent/DE69114117T2/de not_active Expired - Fee Related
- 1991-12-13 AT AT91121403T patent/ATE129409T1/de not_active IP Right Cessation
- 1991-12-13 EP EP91121403A patent/EP0498069B1/de not_active Expired - Lifetime
- 1991-12-16 JP JP3361039A patent/JPH0710778B2/ja not_active Expired - Lifetime
- 1991-12-18 TW TW080109897A patent/TW213862B/zh active
- 1991-12-18 TW TW082105260A patent/TW222584B/zh active
- 1991-12-20 CA CA002058168A patent/CA2058168A1/en not_active Abandoned
- 1991-12-20 KR KR1019910023581A patent/KR100235150B1/ko not_active Expired - Fee Related
-
1993
- 1993-11-18 US US08/154,730 patent/US5616556A/en not_active Expired - Fee Related
-
1994
- 1994-08-31 JP JP6206278A patent/JPH07165601A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0710778B2 (ja) | 1995-02-08 |
| JPH0578254A (ja) | 1993-03-30 |
| KR100235150B1 (ko) | 1999-12-15 |
| DK0498069T3 (da) | 1995-12-04 |
| JPH07165601A (ja) | 1995-06-27 |
| DE69114117D1 (de) | 1995-11-30 |
| KR920012113A (ko) | 1992-07-25 |
| CA2058168A1 (en) | 1992-06-22 |
| EP0498069B1 (de) | 1995-10-25 |
| US5616556A (en) | 1997-04-01 |
| TW222584B (de) | 1994-04-21 |
| EP0498069A2 (de) | 1992-08-12 |
| EP0498069A3 (en) | 1992-11-04 |
| TW213862B (de) | 1993-10-01 |
| DE69114117T2 (de) | 1996-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69114117D1 (de) | Neue Verwendung von Peptidderivat. | |
| DE69114614D1 (de) | Polyethylenglykolderivate, modifizierte Peptide derselben, ihre Herstellung sowie Verwendung der modifizierten Peptide. | |
| GB9309324D0 (en) | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives | |
| DE69230824D1 (de) | Neue tetrapeptidderivate | |
| SE9604786D0 (sv) | New compounds | |
| ES2158537T3 (es) | Derivados de acidos ciclopropilalcanoicos. | |
| ATE165332T1 (de) | Polyenderivate, diese enthaltende pharmazeutische und kosmetische zusammensetzungen und ihre verwendung | |
| PT928788E (pt) | Compostos farmaceuticamente activos | |
| AU6601294A (en) | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | |
| ATE147071T1 (de) | 1,4-disubstituierte piperidinderivate, ihre herstellung und therapeutische verwendung | |
| ATE81009T1 (de) | N-acetyl-3-fluoroneuraminsaeure als antivirales arzneimittel. | |
| DE59208974D1 (de) | Neue pyrazinderivative, ihre herstellung und verwendung | |
| IL111184A (en) | Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin | |
| PL309874A1 (en) | Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives | |
| BR8902929A (pt) | Artigo vendavel | |
| DE69228277D1 (de) | PACAP-Derivate mit c-AMP-produzierenden Eigenschaften | |
| EP0408044A3 (en) | Anti-inflammatory and/or anti-allergic composition comprising glutathione derivatives | |
| CA2082820A1 (en) | Derivatives of 6-aminooctahydroindolizinetriol | |
| ES2057116T3 (es) | Derivados de acido n-(5,6,7,8-tetrahidropirido-(2,3-d)pirimidin-6-ilalcanoil) glutamico. | |
| DE69918098D1 (de) | Neue suesstoffzusammensetzungen | |
| AU636178B2 (en) | 7 (alanylaminothiazol-iminoacetamide) substituted cephalosporin derivatives | |
| DE69001004D1 (de) | Zusammensetzung gegen leberkrankheiten. | |
| DK540589A (da) | Pyrrolidinderivater | |
| ZA912589B (en) | A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |